Table 1.
Patient, tumor and treatment characteristics by surgery type
| Characteristic | Lumpectomy | Mastectomy |
|---|---|---|
| Frequency, n | 302 | 353 |
| Patient age at biopsy, years (P = 0.13) | ||
| Mean (Std. Dev.) | 41.9 (9.4) | 43.0 (9.8) |
| Median | 40.5 | 41.9 |
| Minimum – Maximum | 20.1 – 85.0 | 23.6 – 81.5 |
| Patient age at biopsy, n (%) (P = 0.35) | ||
| ≤ 35 | 74 (24.5) | 71 (20.1) |
| 36 – 50 | 179 (59.3) | 216 (61.2) |
| ≥ 50 | 49 (16.2) | 66 (18.7) |
| Race (P = 0.14) | ||
| White | 278 (92.1) | 312 (88.4) |
| Black | 10 (3.3) | 9 (2.6) |
| Hispanic | 9 (3.0) | 17 (4.8) |
| Other/Unknown | 5 (1.7) | 15 (4.3) |
| Menopausal status at primary (P = 0.003) | ||
| Pre- | 240 (79.5) | 240 (68.0) |
| Post- | 52 (17.2) | 89 (25.2) |
| Peri- | 10 (3.3) | 24 (6.8) |
| BRCA gene mutation (P = 0.01) | ||
| 1 | 197 (65.2) | 197 (55.8) |
| 2 | 105 (34.8) | 156 (44.2) |
| Histology (P = 0.07) | ||
| Infiltrating ductal | 258 (85.4) | 292 (82.7) |
| Lobular or Infiltrating ductal & lobular | 10 (3.3) | 26 (7.4) |
| Medullary or other | 34 (11.2) | 35 (9.9) |
| Clinical stage (P = 0.0007)a | ||
| 1 | 158 (52.3) | 145 (41.1) |
| 2 | 130 (43.1) | 170 (48.2) |
| 3 | 12 (4.0) | 37 (10.5) |
| Unknown | 2 (0.7) | 1 (0.3) |
| Pathologic T-stage (P = 0.001) | ||
| T0/T1 | 214 (70.8) | 203 (57.5) |
| T2 | 81 (26.8) | 125 (35.4) |
| T3 | 4 (1.3) | 16 (4.5) |
| Unknown | 3 (1.0) | 9 (2.6) |
| Estrogen receptor (P = 0.006)a | ||
| Positive | 90 (29.8) | 126 (35.7) |
| Negative | 154 (51.0) | 131 (37.1) |
| Borderline | 3 (1.0) | 3 (0.9) |
| Unknown | 54 (17.9) | 93 (26.4) |
| Progesterone receptor (P = 0.06)a | ||
| Positive | 73 (24.2) | 98 (27.8) |
| Negative | 154 (51.0) | 143 (40.5) |
| Borderline | 3 (1.0) | 0 |
| Unknown | 72 (23.8) | 112 (31.7) |
| Final microscopic surgical margins (P = 0.003)a | ||
| Positive | 16 (5.3) | 4 (1.1) |
| Negative | 248 (82.1) | 272 (77.1) |
| Close | 0 | 4 (1.1) |
| Unknown | 38 (12.6) | 73 (20.7) |
| Nodal surgery | ||
| Yes | 292 (96.7) | 350 (99.2) |
| Total lymph nodes removed (P = 0.95) | ||
| Mean (Std. Dev.) | 14.8 (8.5) | 14.7 (8.5) |
| Median | 14 | 14 |
| Minimum – Maximum | 1 – 48 | 1 – 51 |
| Positive lymph nodes removed (P = 0.004) | ||
| 0 | 210 (71.9) | 223 (63.4) |
| 1 – 3 | 62 (21.2) | 76 (21.6) |
| 4+ | 20 (6.9) | 53 (15.1) |
| No | 10 (3.3) | 1 (0.3) |
| Unknown | 0 | 2 (0.6) |
| Radiotherapy | ||
| No | 0 | 241 (68.3) |
| Yes | 302 (100) | 103 (29.2) |
| Unknown | 0 | 9 (2.6) |
| Chemotherapy (P = 0.20)a | ||
| No | 82 (27.2) | 108 (30.6) |
| Yes | 219 (72.5) | 231 (65.4) |
| Unknown | 1 (0.3) | 14 (4.0) |
| Hormone therapy (P = 0.09)a | ||
| No | 202 (66.9) | 210 (59.5) |
| Yes | 90 (29.8) | 125 (35.4) |
| Tamoxifen | 81 (90.0) | 106 (84.8) |
| Other | 9 (10.0) | 19 (15.2) |
| Unknown | 10 (3.3) | 18 (5.1) |
| Adjuvant therapy (P = 0.35) | ||
| Yes | 254 (84.1) | 287 (81.3) |
| No | 48 (15.9) | 66 (18.7) |
| Bilateral oophorectomy (P = 0.28)a | ||
| No | 141 (46.7) | 150 (42.5) |
| Yes | 161 (53.3) | 203 (57.5) |
| Prior to primary diagnosis | 9 (3.0) | 30 (8.5) |
| After diagnosis, prior to failure | 16 (5.3) | 10 (2.8) |
| After diagnosis, after failure | 12 (4.0) | 9 (2.6) |
| After diagnosis, without failure | 114 (38.0) | 147 (41.6) |
| Timing unknown | 10 (3.3) | 7 (2.0) |
| Prophylactic contralateral mastectomy (P < 0.0001)a | ||
| No | 256 (84.8) | 214 (60.6) |
| Yes | 44 (14.6) | 134 (38.0) |
| Unknown | 2 (0.6) | 5 (1.4) |
a
Comparison between surgical groups made omitting the unknown/missing category.